compounded glp‑1
Cuts Hidden Costs of Prescription Weight Loss
Prescription weight-loss drugs appear cheap on paper, but insurance co-pays, dispensing fees and recent FDA limits on compounding push out-of-pocket costs well beyond the advertised price. In 2026, the FDA proposed rule SC567 that would eliminate 503B bulk compounding of semaglutide, tirzepatide and liraglutide, instantly raising prices by up to